Telix Pharmaceuticals (NASDAQ:TLX) Sets New 12-Month Low – Should You Sell?

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s stock price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $7.58 and last traded at $7.5830, with a volume of 12298 shares trading hands. The stock had previously closed at $7.75.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, October 8th. Citigroup assumed coverage on shares of Telix Pharmaceuticals in a research note on Thursday, September 18th. They issued a “buy” rating and a $22.00 target price on the stock. UBS Group cut their price target on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 23rd. Royal Bank Of Canada assumed coverage on shares of Telix Pharmaceuticals in a research report on Monday, December 15th. They set a “hold” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Telix Pharmaceuticals Stock Down 2.4%

The stock’s 50 day moving average price is $9.43 and its 200-day moving average price is $11.39.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Blair William & Co. IL purchased a new stake in Telix Pharmaceuticals during the 2nd quarter valued at about $217,000. Vanguard Personalized Indexing Management LLC bought a new stake in Telix Pharmaceuticals in the second quarter valued at approximately $297,000. Pier Capital LLC purchased a new stake in shares of Telix Pharmaceuticals during the second quarter valued at approximately $3,037,000. Russell Investments Group Ltd. bought a new position in shares of Telix Pharmaceuticals in the second quarter worth approximately $975,000. Finally, Jane Street Group LLC purchased a new position in shares of Telix Pharmaceuticals in the second quarter worth $564,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.